Literature DB >> 26488041

Cancer of unknown primary site.

Claire M Vajdic, David Goldstein.   

Abstract

BACKGROUND: Cancer of unknown primary (CUP) is the diagnosis given to patients with metastatic cancer with no known site of origin.
OBJECTIVE: This review summarises the current knowledge regarding the epidemiology, diagnosis, treatment and care of CUP. DISCUSSION: The incidence and mortality rates of CUP are declining in Australia. CUP was the twelfth most common cancer and fifth most common cause of cancer death in 2011. Smoking is the only identified risk factor. Incidence patterns implicate reduced access to healthcare and many registered cases have only a clinical diagnosis. Favourable prognosis subtypes with specific clinical and histopathological criteria must be recognised and treated on the basis of the presumed primary site. Emerging data reveal high rates of emergency department admission, hospitalisations and psychological distress, and low rates of specialist consultations for patients with CUP. General practitioners (GPs) have a key role in earlier identification, integrated care and preventing patients with CUP from falling through the cracks.

Entities:  

Mesh:

Year:  2015        PMID: 26488041

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  3 in total

1.  Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia.

Authors:  Louisa G Gordon; C Wood; R W Tothill; P M Webb; P Schofield; L Mileshkin
Journal:  Pharmacoecon Open       Date:  2022-10-17

Review 2.  Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site.

Authors:  Aisha Qaseem; Norina Usman; Joseph S Jayaraj; Rajesh Naidu Janapala; Tooba Kashif
Journal:  Cureus       Date:  2019-09-02

Review 3.  New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary.

Authors:  Paweł Krawczyk; Jacek Jassem; Kamila Wojas-Krawczyk; Maciej Krzakowski; Rafał Dziadziuszko; Włodzimierz Olszewski
Journal:  Cancers (Basel)       Date:  2022-07-14       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.